Latest Breaking News On - Global neuroscience research - Page 2 : comparemela.com

Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs

Updates on PRX012 and PRX123 for treatment of Alzheimer’s disease, and on birtamimab for treatment of AL amyloidosis Remain on track with partnered programs: Bristol Myers Squibb , Roche and.

Novo nordiskEuropean medicines agencyGlobal neuroscience researchProthena corporationDrug administrationDevelopment collaborationBristol myers squibbBusiness updatesFast track designationBristol myersMyers squibbMayo stageOrphan drug designationEuropean medicinesSpecial protocol assessmentFinancial position

Prothena Reports Third Quarter 2023 Financial Results and Business Highlights

Net cash provided by operating and investing activities was $9.1 million in the third quarter and net cash used in operating and investing activities was $84.1 million for the first nine months of 2023; quarter-end cash and restricted cash position was $673.1 millionReceived $55 million payment from Bristol Myers Sq.

United statesMark johnsonNovo nordiskMichael bachnerDrug administrationCorporate communicationsMovement disordersExchange commissionEuropean medicines agencyDevelopment collaborationGlobal neuroscience researchCompany on twitter prothenacorpAmerican society of hematologyInternational congressBristol myers squibbProthena corporation

Prothena Corporation plc: Prothena Reports Third Quarter 2023 Financial Results and Business Highlights

Prothena Corporation plc: Prothena Reports Third Quarter 2023 Financial Results and Business Highlights
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesMark johnsonNovo nordiskMichael bachnerExchange commissionBristol myers squibbInternational congressDevelopment collaborationProthena corporationGlobal neuroscience researchEuropean medicines agencyMovement disordersCompany on twitter prothenacorpAmerican society of hematologyDrug administrationCorporate communications

Prothena Corporation plc: Prothena Announces Bristol Myers Squibb Opt-in of Anti-Tau PRX005 as the First Program from Global Neuroscience Research and Development Collaboration

Prothena Corporation plc: Prothena Announces Bristol Myers Squibb Opt-in of Anti-Tau PRX005 as the First Program from Global Neuroscience Research and Development Collaboration
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesRichard hargreavesJennifer zibudaDevelopment collaborationInvestor relations communicationsCompany on twitter prothenacorpExchange commissionGlobal neuroscience researchBristol myers squibbProthena corporationGene kinneyChief executive officerSenior vice presidentNeuroscience thematic researchProspectus supplementInvestor relations

Investegate |Prothena Corporation plc Announcements | Prothena Corporation plc: Prothena Announces Bristol Myers Squibb Opt-in of Anti-Tau PRX005 as the First Program from Global Neuroscience Research and Development Collaboration

Investegate |Prothena Corporation plc Announcements | Prothena Corporation plc: Prothena Announces Bristol Myers Squibb Opt-in of Anti-Tau PRX005 as the First Program from Global Neuroscience Research and Development Collaboration
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

United statesRichard hargreavesJennifer zibudaBristol myers squibb opt inDevelopment collaborationFirst programInvestor relations communicationsCompany on twitter prothenacorpExchange commissionGlobal neuroscience researchBristol myers squibbProthena corporationProthena announces bristol myers squibb opt inGene kinneyChief executive officerSenior vice president